Atea Pharmaceuticals, Inc. (AVIR) Stock Forecast Nov. 4, 2026
Analysis updated on Nov. 4, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Atea Pharmaceuticals, Inc. (AVIR) stock forecast summary
Our AI scores Atea Pharmaceuticals, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Atea Pharmaceuticals, Inc. is a small-cap company with a market capitalization of $334M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 1.64x is the lowest of the 42 peers that report one.
For AVIR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 358 forecast dates between 2022-08-17 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-08-17 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.3%, sell < +1.7%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AVIR included.
AVIR price chart and AI forecast
How AVIR ranks among 4891 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Atea Pharmaceuticals, Inc. (AVIR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | AVIR | Rank |
|---|---|---|
| Market Cap | $334M | 60/60 |
| P/B Ratio | 1.64x | 42/42 |
| EPS | $-1.91 | – |
| Book Value/Share | $2.55 | – |
Profitability & Margins
| Metric | AVIR | Rank |
|---|---|---|
| ROE | -81.0% | 32/39 |
| ROA | -71.2% | 40/43 |
| ROIC | -89.9% | 42/44 |
| Tax Rate | 3.8% | – |
Financial Health
| Metric | AVIR | Rank |
|---|---|---|
| Current Ratio | 8.13x | 13/58 |
| D/E Ratio | 0.14x | 37/47 |
| Financial Leverage | 1.14x | 38/47 |
| Working Capital | $201M | 50/58 |
Cash Flow
| Metric | AVIR | Rank |
|---|---|---|
| Operating Cash Flow | -$152M | 45/59 |
Income Statement
| Metric | AVIR | Rank |
|---|---|---|
| Operating Income | -$184M | 34/51 |
| Net Income | -$165M | 31/48 |
| R&D Expense | $155M | 52/58 |
Dividend & Shareholder Information
| Metric | AVIR | Rank |
|---|---|---|
| Shares Outstanding | 80M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $229M | 98.5% of assets |
| Cash & Short-term Investments | $77M | 33.0% of assets |
| Total Liabilities | $28M | 12.1% of assets |
| Short-term Debt | $18M | 7.8% of assets |
AVIR quarterly financials and insider trading
Atea Pharmaceuticals, Inc. (AVIR) industry peers
Companies classified under the same SEC industry code as Atea Pharmaceuticals, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| AVIR Atea Pharmaceuticals, Inc. | $334M | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $651.32B | |
| ABBV Abbvie Inc. | $521.11B | |
| MRK Merck & Co., Inc. | $366.03B | |
| NVS Novartis Ag | $308.20B | |
| AZN Astrazeneca Plc | $285.01B | |
| ABT Abbott Laboratories | $190.23B | |
| NVO Novo Nordisk A S | $177.76B | |
| PFE Pfizer Inc | $174.81B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $136.87B | |
| BMY Bristol Myers Squibb Co | $126.14B | |
| SNY Sanofi | $106.33B | |
| REGN Regeneron Pharmaceuticals, Inc. | $98.97B | |
| GSK Gsk Plc | $98.25B | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | |
| TEVA Teva Pharmaceutical Industries Ltd | $47.43B | |
| ONC Beone Medicines Ltd. | $41.07B | |
| GMAB Genmab A/S | $36.34B | |
| ZTS Zoetis Inc. | $34.37B | |
| RPRX Royalty Pharma Plc | $28.77B | |
| ROIV Roivant Sciences Ltd. | $25.92B | |
| UTHR United Therapeutics Corp | $25.57B | |
| INSM Insmed Inc | $22.91B | |
| VTRS Viatris Inc | $21.44B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.42B | |
| ASND Ascendis Pharma A/S | $16.43B | |
| BBIO Bridgebio Pharma, Inc. | $14.42B | |
| JAZZ Jazz Pharmaceuticals Plc | $13.92B | |
| ELAN Elanco Animal Health Inc | $12.28B | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | |
| SMMT Summit Therapeutics Inc. | $11.81B | |
| BMRN Biomarin Pharmaceutical Inc | $10.77B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.96B | |
| TGTX Tg Therapeutics, Inc. | $9.22B | |
| PTGX Protagonist Therapeutics, Inc | $9.02B | |
| CORT Corcept Therapeutics Inc | $8.86B | |
| CYTK Cytokinetics Inc | $8.66B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.54B | |
| SYRE Spyre Therapeutics, Inc. | $8.42B | |
| ALKS Alkermes Plc. | $7.67B | |
| PRAX Praxis Precision Medicines, Inc. | $7.65B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.33B | |
| AXSM Axsome Therapeutics, Inc. | $7.31B | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | |
| ABVX Abivax S.A. | $6.97B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.45B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | |
| ORKA Oruka Therapeutics, Inc. | $6.32B | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | |
| BLTE Belite Bio, Inc | $5.99B | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.61B | |
| MANE Veradermics, Inc | $5.41B | |
| COGT Cogent Biosciences, Inc. | $5.39B | |
| ERAS Erasca, Inc. | $5.12B | |
| PTCT Ptc Therapeutics, Inc. | $5.08B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.63B | |
| TVTX Travere Therapeutics, Inc. | $4.41B | |
| INDV Indivior Pharmaceuticals, Inc. | $4.17B | |
| EWTX Edgewise Therapeutics, Inc. | $4.09B |
Where AVIR sits on the market map
Atea Pharmaceuticals, Inc. (AVIR) stock news
Loading...
Atea Pharmaceuticals, Inc. (AVIR) stock forecast FAQ
What is the Atea Pharmaceuticals, Inc. (AVIR) stock forecast?
Our AI scores Atea Pharmaceuticals, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Atea Pharmaceuticals, Inc. stock predictions?
For AVIR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 358 forecast dates between 2022-08-17 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-08-17 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Atea Pharmaceuticals, Inc. forecasts updated?
Atea Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 4, 2026.
Which companies are Atea Pharmaceuticals, Inc.'s industry peers?
60 issuers in our coverage, AVIR included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.